<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145313</url>
  </required_header>
  <id_info>
    <org_study_id>CN138-582</org_study_id>
    <nct_id>NCT01145313</nct_id>
  </id_info>
  <brief_title>Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder</brief_title>
  <official_title>Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to examine changes in pre/post-augmentation healthcare costs and
      resource utilization in patients diagnosed with major depressive disorder (MDD) who augment
      their current antidepressant therapy with an atypical antipsychotic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pre/post-augmentation healthcare costs and resource utilization among patients diagnosed with MDD who augment antidepressant therapy with an atypical antipsychotic.</measure>
    <time_frame>3 months pre- augmentation.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre/post-augmentation healthcare costs and resource utilization among patients diagnosed with MDD who augment antidepressant therapy with an atypical antipsychotic.</measure>
    <time_frame>3 months post-augmentation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary post-hoc analysis may be conducted to determine differences in outcomes among patients during a longer treatment period, ie 6 month pre- and 6 month post-augmentation.</measure>
    <time_frame>6 month pre-augmentation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A secondary post-hoc analysis may be conducted to determine differences in outcomes among patients during a longer treatment period, ie 6 month pre- and 6 month post-augmentation.</measure>
    <time_frame>6 month post-augmentation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">501</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Patients diagnosed with Major Depressive Disorder</arm_group_label>
    <description>Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The population is identified as patients diagnosed with MDD who are treated with
        antidepressants and subsequently augment with atypical antipsychotic therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet the following criteria will be included in the study:

          -  aged 18 to 64 years

          -  diagnosis of major depressive disorder during the study timeframe (ICD 9 codes 296.2,
             296.3, 311)

          -  evidence of at least 6 consecutive claims for traditional antidepressant therapy with
             a 30 day supply or at least 2 claims with a 90 day supply (consecutive defined as ≤15
             days gap)

          -  must be continually enrolled during the study timeframe and have both medical and
             pharmacy benefits

          -  evidence of at least 4 consecutive claims for an atypical antipsychotic prescription
             with a 30 day supply or 2 claims with a 90 day supply (consecutive defined as ≤15 days
             gap)

          -  evidence of antidepressant therapy for at least 60 consecutive days prior to the
             initiation of atypical antipsychotic

          -  After at least a 60 day trial of traditional antidepressant medications, patient
             augments with an atypical antipsychotic medication for at least 4 months.

        Exclusion Criteria:

        Patients are excluded if they:

          -  have any claims for a diagnosis of schizophrenia, schizoaffective or bipolar disorder
             during the study period

          -  have Electroconvulsive therapy (ECT) during the study period

          -  new augmentation with mood stabilizers, L-thyroxine (T4), L-Thyronine (T3), buspirone,
             stimulant, or others during the post-period (table 1)

          -  are pregnant during the study period

          -  patients with Medicare or Medicaid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/home.aspx</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

